CWA Asset Management Group 13F: Adds $2.3M to GILD Stake

CWA Asset Management Group boosted its position in Gilead Sciences, Inc. GILD by 15,240 shares during the period, according to a Form 13F filing on October 19, 2026. That push brought the firm's total holdings to 78,639 shares valued at about $11.72 million. Gilead closed at $153.07 on the day of the filing.

GILD Gilead Sciences, Inc.

$155.79 ▲ +30.42% year to date

1M 3M YTD

Daily close · Oct 20, 2026

What Changed in CWA Asset Management Group's Gilead Sciences Position

The fund increased its stake by 24.0% from a prior count of 63,399 shares. The total value of the investment sits at $11,721,086 based on the reported figures.

Other Institutional Activity in Gilead Sciences

Other large institutional investors also adjusted their positions in the healthcare firm recently. Caisse de Depot Et Placement Du Quebec grew its holdings by 594,774 shares on May 14, 2026, ending with 1,544,223 shares worth about $195.10 million. Massachusetts Financial Services added 2,058,305 shares on May 14, 2026, holding 6,281,609 shares valued at roughly $799.21 million. ARS Wealth Advisors Group picked up 1,458 shares on October 16, 2026, bringing its total to 1,458 shares worth about $217,280.

Gilead Sciences, Inc. Stock Up 0.2%

Gilead recently traded around $156.51 as of October 21, 2026, sitting above its 50-day moving average of $147.23 and well above its 200-day moving average of $138.18. The stock trades below its 52-week high of $160.51 and well above its low of $114.02.

Recent Earnings

Gilead Sciences reported trailing twelve-month revenue of $30.46 billion. The firm posted a negative net margin and return on equity over the period, resulting in a negative trailing EPS of $2.65. Investors look ahead to the company's next earnings report on October 29, 2026.

Dividend

The company pays an annual dividend rate of $3.28 per share, which translates to a 2.14% dividend yield.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders completed several transactions in recent months. Johanna Mercier sold 3,000 shares on September 15, 2026. Andrew D Dickinson sold 3,000 shares at $145.29 on September 15, 2026, for a total of $435,870. Later, Johanna Mercier sold 3,000 shares at $156.22 on October 15, 2026, under a planned schedule, worth $468,660. Andrew D Dickinson also sold 3,000 shares at $156.22 on October 15, 2026, under a planned routine, valued at $468,660.

Analysts Set New Price Targets

Analyst firms updated their views on the stock ahead of the filing. Truist Securities maintained a buy rating on October 7, 2026, lifting its target to $158.00 from $150.00. JP Morgan kept an overweight rating on October 7, 2026, raising its target to $170.00 from $160.00. Morgan Stanley maintained an overweight rating on October 7, 2026, adjusting its target to $163.00 from $165.00. RBC Capital maintained a sector perform rating on October 8, 2026, moving its target to $126.00 from $123.00. Cantor Fitzgerald reiterated an overweight rating on October 8, 2026, with a $155.00 target. Wall Street analysts hold a consensus buy rating on the stock with a mean price target of $160.15 across 26 analyst opinions.

About Gilead Sciences

Gilead Sciences, Inc. is a Foster City, California-based biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs. The company's portfolio includes treatments for HIV-1 infections such as Biktarvy, Descovy, and Sunlenca.

Bottom Line

Investors will look closely at Gilead's upcoming earnings release on October 29, 2026, for fresh guidance on the drug maker's financial path. The stock continues to trade near the upper end of its 52-week range as institutional holders adjust their exposure.